Introduction There are no ongoing clinical trials investigating bevacizumab efficacy beyond disease progression in platinum-resistant recurrent ovarian cancer; however, improving outcomes in these patients is a critical unmet need.
Methods This open-label, randomized phase II trial (JGOG3023; UMIN000017247) enrolled patients aged ≥20 years with histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with platinum-resistant disease (progression occurring ≤6 months from completing ≥3 platinum cycles, including bevacizumab). Patients were randomized 1:1 to single-agent chemotherapy (group A) or single-agent chemotherapy combined with bevacizumab (group B). The primary endpoint was investigator-assessed PFS. Secondary endpoints included OS, ORR, and safety.
Results Patient characteristics were balanced between group A (n=51) and group B (n=52). Median PFS was longer in group B versus group A (4.0 [95% CI: 3.0–5.7] vs 3.1 [2.5–4.6] months; HR, 0.54 [0.32–0.90]; one-sided p=0.0082) (figure 1). Maximum tumor diameter and ascites were significantly associated with greater prolongation in PFS in group B (figure 2). Median OS was numerically longer in group B versus group A (15.3 vs 11.3 months; HR, 0.67 [0.38–1.17]; two-sided p=0.1556). ORR was 13.7% and 25.0% in group A and B, respectively. The safety profile was similar across both groups (table 1).
Conclusion These results suggest chemotherapy combined with bevacizumab has efficacy beyond disease progression. A phase III trial is warranted to confirm our findings.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.